The Hit-to-Lead (H2L) in Drug Discovery segmentation by application reflects the therapeutic focus of early‑stage programs and drives the allocation of R&D budgets. Oncology dominates the landscape, accounting for roughly 35 % of total spend, because of high unmet needs and substantial venture funding that accelerate hit‑to‑lead pipelines. Infectious diseases follow with an estimated 25 % share, propelled by global health initiatives and the urgency of antimicrobial resistance. Central nervous system projects contribute about 20 % of the market, despite historically low success rates, as advances in blood‑brain barrier modeling improve hit validation. Metabolic disorders represent 15 % of the market, benefitting from rising prevalence of diabetes and obesity, which incentivize early‑stage lead generation. The remaining 5 % falls under Other therapeutic areas such as ophthalmology and rare diseases, where niche pipelines still require robust hit‑to‑lead capabilities. Collectively, these application segments define the demand curve for screening libraries, assay platforms, and computational tools, thereby shaping the overall size of the H2L market.